Industry Research Reports

Home > Reports > Medical Care > Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Industry: Medical Care

Published Date: 2025-05-24

Pages: 139 Pages

Report ld: 4744522

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Peptide Therapeutics Market Size(US$)

CAGR 2025-2031

9.0%

Market Size,2031

USD 74,320

Million

Market Snapshot

Market Size in 2025 (Value)

US$ 44,320 million

Market Forecast in 2031(Value)

US$ 74,320 million

CAGR

9.0%

Years Considered

2020-2031

Base Year

2025

Forecast Period

2025-2031

Source: Secondary research, interviews with experts, and QYResearch analysis

The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.

Peptide therapeutics are a class of pharmaceutical drugs composed of short chains of amino acids, typically ranging from 2 to 50 residues, that mimic natural peptides in the body. These drugs are designed to interact with specific cellular targets, such as receptors, enzymes, or ion channels, to regulate physiological functions. Due to their high specificity, low toxicity, and favorable safety profiles, peptide drugs are widely used in the treatment of various diseases, including cancer, diabetes, cardiovascular diseases, and infectious conditions. With advances in peptide engineering, formulation, and delivery technologies, peptide therapeutics have become a growing segment of the biopharmaceutical industry.

The Peptide Therapeutics market is driven by the increasing demand for highly specific and efficient treatments for a wide range of diseases, including cancer, diabetes, cardiovascular conditions, and rare genetic disorders. Peptides, due to their high selectivity, low immunogenicity, and close resemblance to natural biological molecules, are well-suited for targeted therapy with fewer side effects. Technological advancements in peptide synthesis, modification, and drug delivery systems have enhanced their stability and extended their half-life, making them more viable for clinical use. Additionally, the growing investment in biopharmaceutical research and development, along with a favorable regulatory environment for innovative therapies, is accelerating the development and approval of peptide-based drugs.

Despite these advantages, the Peptide Therapeutics market faces several challenges, particularly related to drug delivery and manufacturing. Peptides are generally unstable in the gastrointestinal tract and are rapidly degraded by enzymes, limiting their oral bioavailability and often requiring parenteral administration. This can affect patient compliance and limit market penetration. Moreover, the complex and costly manufacturing processes for peptide drugs, including synthesis, purification, and formulation, pose economic and technical barriers, especially for smaller biotech firms. Overcoming these limitations through innovative formulation strategies and cost-efficient production methods is critical for ensuring broader clinical adoption and long-term market growth.

Global Peptide Therapeutics key players include Sanofi, Novo Nordisk, Takeda, Eli Lilly, Ipsen, etc. Global top five manufacturers hold a share about 65%. North America is the largest market, with a share about 55%, followed by Europe and Asia-Pacific, both have a share about 40 percent. In terms of product, Injection is the largest segment, with a share about 70%. And in terms of application, the largest application is Cancer, followed by Central Nervous System.

This report aims to provide a comprehensive presentation of the global market for Peptide Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peptide Therapeutics by region & country, by Type, and by Application.

The Peptide Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Therapeutics.

MARKET SEGMENTATION

By Company

Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
J & J
Aurinia Pharmaceuticals
BioMarin Pharmaceutical
Apellis Pharmaceuticals
Lantheus
CSL Vifor Group

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Injection
Oral
Other

Segment by Application

Cancer
Metabolic Disorders
Central Nervous System
Other

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Peptide Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Peptide Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Peptide Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Peptide Therapeutics Product Introduction

1.2 Global Peptide Therapeutics Market Size Forecast (2020-2031)

1.3 Peptide Therapeutics Market Trends & Drivers

1.3.1 Peptide Therapeutics Industry Trends

1.3.2 Peptide Therapeutics Market Drivers & Opportunity

1.3.3 Peptide Therapeutics Market Challenges

1.3.4 Peptide Therapeutics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Peptide Therapeutics Players Revenue Ranking (2024)

2.2 Global Peptide Therapeutics Revenue by Company (2020-2025)

2.3 Key Companies Peptide Therapeutics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Peptide Therapeutics Product Offered

2.5 Key Companies Time to Begin Mass Production of Peptide Therapeutics

2.6 Peptide Therapeutics Market Competitive Analysis

2.6.1 Peptide Therapeutics Market Concentration Rate (2020-2025)

2.6.2 Global 5 and 10 Largest Companies by Peptide Therapeutics Revenue in 2024

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Therapeutics as of 2024)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Injection

3.1.2 Oral

3.1.3 Other

3.2 Global Peptide Therapeutics Sales Value by Type

3.2.1 Global Peptide Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Peptide Therapeutics Sales Value, by Type (2020-2031)

3.2.3 Global Peptide Therapeutics Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Cancer

4.1.2 Metabolic Disorders

4.1.3 Central Nervous System

4.1.4 Other

4.2 Global Peptide Therapeutics Sales Value by Application

4.2.1 Global Peptide Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Peptide Therapeutics Sales Value, by Application (2020-2031)

4.2.3 Global Peptide Therapeutics Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

5.1 Global Peptide Therapeutics Sales Value by Region

5.1.1 Global Peptide Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Peptide Therapeutics Sales Value by Region (2020-2025)

5.1.3 Global Peptide Therapeutics Sales Value by Region (2026-2031)

5.1.4 Global Peptide Therapeutics Sales Value by Region (%), (2020-2031)

5.2 North America

5.2.1 North America Peptide Therapeutics Sales Value, 2020-2031

5.2.2 North America Peptide Therapeutics Sales Value by Country (%), 2024 VS 2031

5.3 Europe

5.3.1 Europe Peptide Therapeutics Sales Value, 2020-2031

5.3.2 Europe Peptide Therapeutics Sales Value by Country (%), 2024 VS 2031

5.4 Asia Pacific

5.4.1 Asia Pacific Peptide Therapeutics Sales Value, 2020-2031

5.4.2 Asia Pacific Peptide Therapeutics Sales Value by Region (%), 2024 VS 2031

5.5 South America

5.5.1 South America Peptide Therapeutics Sales Value, 2020-2031

5.5.2 South America Peptide Therapeutics Sales Value by Country (%), 2024 VS 2031

5.6 Middle East & Africa

5.6.1 Middle East & Africa Peptide Therapeutics Sales Value, 2020-2031

5.6.2 Middle East & Africa Peptide Therapeutics Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Peptide Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Peptide Therapeutics Sales Value, 2020-2031

6.3 United States

6.3.1 United States Peptide Therapeutics Sales Value, 2020-2031

6.3.2 United States Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Peptide Therapeutics Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Peptide Therapeutics Sales Value, 2020-2031

6.4.2 Europe Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Peptide Therapeutics Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Peptide Therapeutics Sales Value, 2020-2031

6.5.2 China Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

6.5.3 China Peptide Therapeutics Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Peptide Therapeutics Sales Value, 2020-2031

6.6.2 Japan Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Peptide Therapeutics Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Peptide Therapeutics Sales Value, 2020-2031

6.7.2 South Korea Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Peptide Therapeutics Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Peptide Therapeutics Sales Value, 2020-2031

6.8.2 Southeast Asia Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Peptide Therapeutics Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Peptide Therapeutics Sales Value, 2020-2031

6.9.2 India Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

6.9.3 India Peptide Therapeutics Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 Sanofi

7.1.1 Sanofi Profile

7.1.2 Sanofi Main Business

7.1.3 Sanofi Peptide Therapeutics Products, Services and Solutions

7.1.4 Sanofi Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.1.5 Sanofi Recent Developments

7.2 Teva

7.2.1 Teva Profile

7.2.2 Teva Main Business

7.2.3 Teva Peptide Therapeutics Products, Services and Solutions

7.2.4 Teva Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.2.5 Teva Recent Developments

7.3 Novo Nordisk

7.3.1 Novo Nordisk Profile

7.3.2 Novo Nordisk Main Business

7.3.3 Novo Nordisk Peptide Therapeutics Products, Services and Solutions

7.3.4 Novo Nordisk Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.3.5 Novo Nordisk Recent Developments

7.4 Takeda

7.4.1 Takeda Profile

7.4.2 Takeda Main Business

7.4.3 Takeda Peptide Therapeutics Products, Services and Solutions

7.4.4 Takeda Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.4.5 Takeda Recent Developments

7.5 Eli Lilly

7.5.1 Eli Lilly Profile

7.5.2 Eli Lilly Main Business

7.5.3 Eli Lilly Peptide Therapeutics Products, Services and Solutions

7.5.4 Eli Lilly Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.5.5 Eli Lilly Recent Developments

7.6 AstraZeneca

7.6.1 AstraZeneca Profile

7.6.2 AstraZeneca Main Business

7.6.3 AstraZeneca Peptide Therapeutics Products, Services and Solutions

7.6.4 AstraZeneca Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.6.5 AstraZeneca Recent Developments

7.7 Novartis

7.7.1 Novartis Profile

7.7.2 Novartis Main Business

7.7.3 Novartis Peptide Therapeutics Products, Services and Solutions

7.7.4 Novartis Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.7.5 Novartis Recent Developments

7.8 AbbVie

7.8.1 AbbVie Profile

7.8.2 AbbVie Main Business

7.8.3 AbbVie Peptide Therapeutics Products, Services and Solutions

7.8.4 AbbVie Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.8.5 AbbVie Recent Developments

7.9 Ipsen

7.9.1 Ipsen Profile

7.9.2 Ipsen Main Business

7.9.3 Ipsen Peptide Therapeutics Products, Services and Solutions

7.9.4 Ipsen Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.9.5 Ipsen Recent Developments

7.10 Ferring

7.10.1 Ferring Profile

7.10.2 Ferring Main Business

7.10.3 Ferring Peptide Therapeutics Products, Services and Solutions

7.10.4 Ferring Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.10.5 Ferring Recent Developments

7.11 Merck

7.11.1 Merck Profile

7.11.2 Merck Main Business

7.11.3 Merck Peptide Therapeutics Products, Services and Solutions

7.11.4 Merck Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.11.5 Merck Recent Developments

7.12 The Medicines

7.12.1 The Medicines Profile

7.12.2 The Medicines Main Business

7.12.3 The Medicines Peptide Therapeutics Products, Services and Solutions

7.12.4 The Medicines Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.12.5 The Medicines Recent Developments

7.13 J & J

7.13.1 J & J Profile

7.13.2 J & J Main Business

7.13.3 J & J Peptide Therapeutics Products, Services and Solutions

7.13.4 J & J Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.13.5 J & J Recent Developments

7.14 Aurinia Pharmaceuticals

7.14.1 Aurinia Pharmaceuticals Profile

7.14.2 Aurinia Pharmaceuticals Main Business

7.14.3 Aurinia Pharmaceuticals Peptide Therapeutics Products, Services and Solutions

7.14.4 Aurinia Pharmaceuticals Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.14.5 Aurinia Pharmaceuticals Recent Developments

7.15 BioMarin Pharmaceutical

7.15.1 BioMarin Pharmaceutical Profile

7.15.2 BioMarin Pharmaceutical Main Business

7.15.3 BioMarin Pharmaceutical Peptide Therapeutics Products, Services and Solutions

7.15.4 BioMarin Pharmaceutical Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.15.5 BioMarin Pharmaceutical Recent Developments

7.16 Apellis Pharmaceuticals

7.16.1 Apellis Pharmaceuticals Profile

7.16.2 Apellis Pharmaceuticals Main Business

7.16.3 Apellis Pharmaceuticals Peptide Therapeutics Products, Services and Solutions

7.16.4 Apellis Pharmaceuticals Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.16.5 Apellis Pharmaceuticals Recent Developments

7.17 Lantheus

7.17.1 Lantheus Profile

7.17.2 Lantheus Main Business

7.17.3 Lantheus Peptide Therapeutics Products, Services and Solutions

7.17.4 Lantheus Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.17.5 Lantheus Recent Developments

7.18 CSL Vifor Group

7.18.1 CSL Vifor Group Profile

7.18.2 CSL Vifor Group Main Business

7.18.3 CSL Vifor Group Peptide Therapeutics Products, Services and Solutions

7.18.4 CSL Vifor Group Peptide Therapeutics Revenue (US$ Million) & (2020-2025)

7.18.5 CSL Vifor Group Recent Developments

8 Industry Chain Analysis

8.1 Peptide Therapeutics Industrial Chain

8.2 Peptide Therapeutics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Peptide Therapeutics Sales Model

8.5.2 Sales Channel

8.5.3 Peptide Therapeutics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Peptide Therapeutics Market Trends

Table 2. Peptide Therapeutics Market Drivers & Opportunity

Table 3. Peptide Therapeutics Market Challenges

Table 4. Peptide Therapeutics Market Restraints

Table 5. Global Peptide Therapeutics Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Peptide Therapeutics Revenue Market Share by Company (2020-2025)

Table 7. Key Companies Peptide Therapeutics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Peptide Therapeutics Product Type

Table 9. Key Companies Time to Begin Mass Production of Peptide Therapeutics

Table 10. Global Peptide Therapeutics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Therapeutics as of 2024)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Peptide Therapeutics Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 14. Global Peptide Therapeutics Sales Value by Type (2020-2025) & (US$ Million)

Table 15. Global Peptide Therapeutics Sales Value by Type (2026-2031) & (US$ Million)

Table 16. Global Peptide Therapeutics Sales Market Share in Value by Type (2020-2025)

Table 17. Global Peptide Therapeutics Sales Market Share in Value by Type (2026-2031)

Table 18. Global Peptide Therapeutics Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 19. Global Peptide Therapeutics Sales Value by Application (2020-2025) & (US$ Million)

Table 20. Global Peptide Therapeutics Sales Value by Application (2026-2031) & (US$ Million)

Table 21. Global Peptide Therapeutics Sales Market Share in Value by Application (2020-2025)

Table 22. Global Peptide Therapeutics Sales Market Share in Value by Application (2026-2031)

Table 23. Global Peptide Therapeutics Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 24. Global Peptide Therapeutics Sales Value by Region (2020-2025) & (US$ Million)

Table 25. Global Peptide Therapeutics Sales Value by Region (2026-2031) & (US$ Million)

Table 26. Global Peptide Therapeutics Sales Value by Region (2020-2025) & (%)

Table 27. Global Peptide Therapeutics Sales Value by Region (2026-2031) & (%)

Table 28. Key Countries/Regions Peptide Therapeutics Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 29. Key Countries/Regions Peptide Therapeutics Sales Value, (2020-2025) & (US$ Million)

Table 30. Key Countries/Regions Peptide Therapeutics Sales Value, (2026-2031) & (US$ Million)

Table 31. Sanofi Basic Information List

Table 32. Sanofi Description and Business Overview

Table 33. Sanofi Peptide Therapeutics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Peptide Therapeutics Business of Sanofi (2020-2025)

Table 35. Sanofi Recent Developments

Table 36. Teva Basic Information List

Table 37. Teva Description and Business Overview

Table 38. Teva Peptide Therapeutics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Peptide Therapeutics Business of Teva (2020-2025)

Table 40. Teva Recent Developments

Table 41. Novo Nordisk Basic Information List

Table 42. Novo Nordisk Description and Business Overview

Table 43. Novo Nordisk Peptide Therapeutics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Peptide Therapeutics Business of Novo Nordisk (2020-2025)

Table 45. Novo Nordisk Recent Developments

Table 46. Takeda Basic Information List

Table 47. Takeda Description and Business Overview

Table 48. Takeda Peptide Therapeutics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Peptide Therapeutics Business of Takeda (2020-2025)

Table 50. Takeda Recent Developments

Table 51. Eli Lilly Basic Information List

Table 52. Eli Lilly Description and Business Overview

Table 53. Eli Lilly Peptide Therapeutics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Peptide Therapeutics Business of Eli Lilly (2020-2025)

Table 55. Eli Lilly Recent Developments

Table 56. AstraZeneca Basic Information List

Table 57. AstraZeneca Description and Business Overview

Table 58. AstraZeneca Peptide Therapeutics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Peptide Therapeutics Business of AstraZeneca (2020-2025)

Table 60. AstraZeneca Recent Developments

Table 61. Novartis Basic Information List

Table 62. Novartis Description and Business Overview

Table 63. Novartis Peptide Therapeutics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Peptide Therapeutics Business of Novartis (2020-2025)

Table 65. Novartis Recent Developments

Table 66. AbbVie Basic Information List

Table 67. AbbVie Description and Business Overview

Table 68. AbbVie Peptide Therapeutics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Peptide Therapeutics Business of AbbVie (2020-2025)

Table 70. AbbVie Recent Developments

Table 71. Ipsen Basic Information List

Table 72. Ipsen Description and Business Overview

Table 73. Ipsen Peptide Therapeutics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Peptide Therapeutics Business of Ipsen (2020-2025)

Table 75. Ipsen Recent Developments

Table 76. Ferring Basic Information List

Table 77. Ferring Description and Business Overview

Table 78. Ferring Peptide Therapeutics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Peptide Therapeutics Business of Ferring (2020-2025)

Table 80. Ferring Recent Developments

Table 81. Merck Basic Information List

Table 82. Merck Description and Business Overview

Table 83. Merck Peptide Therapeutics Products, Services and Solutions

Table 84. Revenue (US$ Million) in Peptide Therapeutics Business of Merck (2020-2025)

Table 85. Merck Recent Developments

Table 86. The Medicines Basic Information List

Table 87. The Medicines Description and Business Overview

Table 88. The Medicines Peptide Therapeutics Products, Services and Solutions

Table 89. Revenue (US$ Million) in Peptide Therapeutics Business of The Medicines (2020-2025)

Table 90. The Medicines Recent Developments

Table 91. J & J Basic Information List

Table 92. J & J Description and Business Overview

Table 93. J & J Peptide Therapeutics Products, Services and Solutions

Table 94. Revenue (US$ Million) in Peptide Therapeutics Business of J & J (2020-2025)

Table 95. J & J Recent Developments

Table 96. Aurinia Pharmaceuticals Basic Information List

Table 97. Aurinia Pharmaceuticals Description and Business Overview

Table 98. Aurinia Pharmaceuticals Peptide Therapeutics Products, Services and Solutions

Table 99. Revenue (US$ Million) in Peptide Therapeutics Business of Aurinia Pharmaceuticals (2020-2025)

Table 100. Aurinia Pharmaceuticals Recent Developments

Table 101. BioMarin Pharmaceutical Basic Information List

Table 102. BioMarin Pharmaceutical Description and Business Overview

Table 103. BioMarin Pharmaceutical Peptide Therapeutics Products, Services and Solutions

Table 104. Revenue (US$ Million) in Peptide Therapeutics Business of BioMarin Pharmaceutical (2020-2025)

Table 105. BioMarin Pharmaceutical Recent Developments

Table 106. Apellis Pharmaceuticals Basic Information List

Table 107. Apellis Pharmaceuticals Description and Business Overview

Table 108. Apellis Pharmaceuticals Peptide Therapeutics Products, Services and Solutions

Table 109. Revenue (US$ Million) in Peptide Therapeutics Business of Apellis Pharmaceuticals (2020-2025)

Table 110. Apellis Pharmaceuticals Recent Developments

Table 111. Lantheus Basic Information List

Table 112. Lantheus Description and Business Overview

Table 113. Lantheus Peptide Therapeutics Products, Services and Solutions

Table 114. Revenue (US$ Million) in Peptide Therapeutics Business of Lantheus (2020-2025)

Table 115. Lantheus Recent Developments

Table 116. CSL Vifor Group Basic Information List

Table 117. CSL Vifor Group Description and Business Overview

Table 118. CSL Vifor Group Peptide Therapeutics Products, Services and Solutions

Table 119. Revenue (US$ Million) in Peptide Therapeutics Business of CSL Vifor Group (2020-2025)

Table 120. CSL Vifor Group Recent Developments

Table 121. Key Raw Materials Lists

Table 122. Raw Materials Key Suppliers Lists

Table 123. Peptide Therapeutics Downstream Customers

Table 124. Peptide Therapeutics Distributors List

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

List of Figures

Figure 1. Peptide Therapeutics Product Picture

Figure 2. Global Peptide Therapeutics Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Peptide Therapeutics Sales Value (2020-2031) & (US$ Million)

Figure 4. Peptide Therapeutics Report Years Considered

Figure 5. Global Peptide Therapeutics Players Revenue Ranking (2024) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Peptide Therapeutics Revenue in 2024

Figure 7. Peptide Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 8. Injection Picture

Figure 9. Oral Picture

Figure 10. Other Picture

Figure 11. Global Peptide Therapeutics Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 12. Global Peptide Therapeutics Sales Value Market Share by Type, 2024 & 2031

Figure 13. Product Picture of Cancer

Figure 14. Product Picture of Metabolic Disorders

Figure 15. Product Picture of Central Nervous System

Figure 16. Product Picture of Other

Figure 17. Global Peptide Therapeutics Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 18. Global Peptide Therapeutics Sales Value Market Share by Application, 2024 & 2031

Figure 19. North America Peptide Therapeutics Sales Value (2020-2031) & (US$ Million)

Figure 20. North America Peptide Therapeutics Sales Value by Country (%), 2024 VS 2031

Figure 21. Europe Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 22. Europe Peptide Therapeutics Sales Value by Country (%), 2024 VS 2031

Figure 23. Asia Pacific Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 24. Asia Pacific Peptide Therapeutics Sales Value by Region (%), 2024 VS 2031

Figure 25. South America Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 26. South America Peptide Therapeutics Sales Value by Country (%), 2024 VS 2031

Figure 27. Middle East & Africa Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 28. Middle East & Africa Peptide Therapeutics Sales Value by Country (%), 2024 VS 2031

Figure 29. Key Countries/Regions Peptide Therapeutics Sales Value (%), (2020-2031)

Figure 30. United States Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 31. United States Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 32. United States Peptide Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 33. Europe Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 34. Europe Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 35. Europe Peptide Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 36. China Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 37. China Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 38. China Peptide Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 39. Japan Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 40. Japan Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 41. Japan Peptide Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 42. South Korea Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 43. South Korea Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 44. South Korea Peptide Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 45. Southeast Asia Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 46. Southeast Asia Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 47. Southeast Asia Peptide Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 48. India Peptide Therapeutics Sales Value, (2020-2031) & (US$ Million)

Figure 49. India Peptide Therapeutics Sales Value by Type (%), 2024 VS 2031

Figure 50. India Peptide Therapeutics Sales Value by Application (%), 2024 VS 2031

Figure 51. Peptide Therapeutics Industrial Chain

Figure 52. Peptide Therapeutics Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

What is the annual compound growth rate of the global Peptide Therapeutics market size from 2025 to 2031? zhanKai

The annual compound growth rate of the global Peptide Therapeutics market is 9.0% 2025 to 2031.

Which region is expected to have the highest market share? shouQi

What was the global market size of Peptide Therapeutics in 2025? shouQi

What was the global market size of Peptide Therapeutics in 2031? shouQi

Which companies rank high in the global Peptide Therapeutics market? shouQi

Related Reports

Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 80340 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-02-14
Pages: 152
USD 4900.00
(Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Peptide Therapeutics market size was US$ 44320 million in 2025 and is forecast to reach a readjusted size of US$ 80340 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.
Published Date: 2026-02-14
Pages: 108
USD 4250.00
(Single User License)
Global Peptide Therapeutics Market Research Report 2026
The global Peptide Therapeutics market was valued at US$ 44320 million in 2025 and is anticipated to reach US$ 80340 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-02-14
Pages: 131
USD 2900.00
(Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published Date: 2026-02-14
Pages: 122
USD 3950.00
(Single User License)
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 41000 million in 2024 to US$ 74320 million by 2031, at a CAGR of 9.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-09-11
Pages: 151
USD 4900.00
(Single User License)
Global Peptide Therapeutics Market Insights, Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 74320 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
Published Date: 2025-05-24
Pages: 158
USD 4900.00
(Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Peptide Therapeutics market size was US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-05-24
Pages: 110
USD 4250.00
(Single User License)
Global Peptide Therapeutics Market Research Report 2025
The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published Date: 2025-05-24
Pages: 94
USD 2900.00
(Single User License)
Global Peptide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Peptide Therapeutics was estimated to be worth US$ 41000 million and is forecast to reach approximately US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 143
USD 5900.00
(Single User License)
Peptide Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 120
USD 3950.00
(Single User License)

Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 80340 million by 2032, at a CAGR of 9.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-02-14
Pages: 152
USD 4900.00 (Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Peptide Therapeutics market size was US$ 44320 million in 2025 and is forecast to reach a readjusted size of US$ 80340 million by 2032 with a CAGR of 9.0% during the forecast period 2026-2032.
Published: 2026-02-14
Pages: 108
USD 4250.00 (Single User License)
Global Peptide Therapeutics Market Research Report 2026
The global Peptide Therapeutics market was valued at US$ 44320 million in 2025 and is anticipated to reach US$ 80340 million by 2032, at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-02-14
Pages: 131
USD 2900.00 (Single User License)
Peptide Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Peptide Therapeutics was estimated to be worth US$ 44320 million in 2025 and is projected to reach US$ 80340 million, growing at a CAGR of 9.0% from 2026 to 2032.
Published: 2026-02-14
Pages: 122
USD 3950.00 (Single User License)
Global Peptide Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 41000 million in 2024 to US$ 74320 million by 2031, at a CAGR of 9.0% (2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-09-11
Pages: 151
USD 4900.00 (Single User License)
Global Peptide Therapeutics Market Insights, Forecast to 2031
The global Peptide Therapeutics market is projected to grow from US$ 44320 million in 2025 to US$ 74320 million by 2031, at a Compound Annual Growth Rate (CAGR) of 9.0% during the forecast period.
Published: 2025-05-24
Pages: 158
USD 4900.00 (Single User License)
Global Peptide Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Peptide Therapeutics market size was US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-05-24
Pages: 110
USD 4250.00 (Single User License)
Global Peptide Therapeutics Market Research Report 2025
The global market for Peptide Therapeutics was valued at US$ 41000 million in the year 2024 and is projected to reach a revised size of US$ 74320 million by 2031, growing at a CAGR of 9.0% during the forecast period.
Published: 2025-05-24
Pages: 94
USD 2900.00 (Single User License)
Global Peptide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Peptide Therapeutics was estimated to be worth US$ 41000 million and is forecast to reach approximately US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 143
USD 5900.00 (Single User License)
Peptide Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Therapeutics was estimated to be worth US$ 41000 million in 2024 and is forecast to a readjusted size of US$ 74320 million by 2031 with a CAGR of 9.0% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 120
USD 3950.00 (Single User License)